MIRIKIZUMAB - A NEW OPTION IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

被引：0

作者：

Olszewski, Jakub ^{[1
]}

Kozon, Katarzyna ^{[1
]}

Sitnik, Magdalena ^{[1
]}

Herjan, Katarzyna ^{[2
]}

Mikolap, Karolina ^{[3
]}

Gastol, Bartlomiej ^{[4
]}

Bara, Maciej ^{[5
]}

Armanski, Piotr ^{[6
]}

Sawczuk, Marcin ^{[7
]}

机构：

[1] Masovian Brodnowski Hosp, PL-03242 Warsaw, Poland

[2] Prof W Orlowski Mem Hosp, PL-00401 Warsaw, Poland

[3] Wolski Hosp Warsaw, PL-01211 Warsaw, Poland

[4] Masovian Specialist Hosp Ostroleka, PL-07410 Ostroleka, Poland

[5] Med Univ Warsaw, Infant Jesus Clin Hosp, PL-02005 Warsaw, Poland

[6] Dist Hosp Sochaczew, PL-96500 Sochaczew, Poland

[7] Med Univ Gdansk, Clin Ctr, PL-80952 Gdansk, Poland

来源：

PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期

关键词：

mirikizumab; IL-23; ulcerative colitis; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; INTERLEUKIN-23; DIAGNOSIS; INDUCTION;

D O I：

10.56782/pps.262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and "IL-23" and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.

引用

页码：178 / 185

页数：8

共 50 条

[21] Nanomedicines for the treatment of inflammatory bowel diseases
Ali, Hussain
Collnot, Eva-Maria
Windbergs, Maike
Lehr, Claus-Michael
EUROPEAN JOURNAL OF NANOMEDICINE, 2013, 5 (01) : 23 - 38
[22] Treatment Strategies in Inflammatory Bowel Diseases
Stallmach, Andreas
Atreya, Raja
Grunert, Philip Christian
Stallhofer, Johannes
de Laffolie, Jan
Schmidt, Carsten
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (45): : 768 - 778
[23] Treatment of chronic inflammatory bowel diseases
Lemann, Marc
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2007, 191 (06): : 1125 - 1141
[24] Diet in Treatment of Inflammatory Bowel Diseases
Sasson, Alexa N.
Ananthakrishnan, Ashwin N.
Raman, Maitreyi
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (03) : 425 - +
[25] Food as Treatment of Inflammatory Bowel Diseases
Maldonado-Contreras, Ana
INFECTION AND IMMUNITY, 2022, 90 (05)
[26] New paths for inflammatory bowel diseases
不详
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (06) : 572 - 572
[27] A new hypothesis on inflammatory bowel diseases
El-Tawil, Am
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2009, 13 (01) : 66 - 66
[28] Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Song, Hyo Yeop
Seo, Geom Seog
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (09): : 605 - 613
[29] Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases?
Chateau, Thomas
Le Berre, Catherine
Peyrin-Biroulet, Laurent
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (05) : 1030 - 1032
[30] Extracellular Vesicles: A New Nano Tool for the Treatment of Inflammatory Bowel Diseases
Tandra, Nitin
Wu, Peipei
Hu, Xinyuan
Mao, Fei
Xu, Wenrong
Qian, Hui
CURRENT NANOSCIENCE, 2019, 15 (06) : 589 - 595

← 1 2 3 4 5 →